Generic Luxiq® Launches

Released: 01/21/2013   By: Mike Partridge, RPh

On January 15, 2013, Perrigo received final FDA approval for and commenced shipping the generic equivalent for GlaxoSmithKlines’s branded product, Luxiq® (betamethasone valerate) foam. Luxiq® had estimated total U.S. annual sales of approximately $30 million.

Betamethasone valerate foam is used to treat skin conditions of the scalp (such as psoriasis, seborrhea). Betamethasone valerate foam works by decreasing the swelling (inflammation), itching, and redness.